Prostate Cancer
Approximately 1.5 million new cases of prostate cancer are diagnosed annually worldwide.
Approximately 75% of patients present with cancer localized to the prostate, which is associated with a 5-year survival rate of nearly 100%.
Management includes active surveillance, prostatectomy, or radiation therapy, depending on risk of progression.
Approximately 10% of patients present with metastatic prostate cancer, which has a 5-year survival rate of 37%.
First-line therapies for metastatic prostate cancer include androgen deprivation and novel androgen receptor pathway inhibitors, and chemotherapy for appropriate patients.
